Compare Moderna, Inc. (MRNA) vs Synchrony Financial (SYF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Synchrony Financial — how do they compare? Moderna, Inc. trades at $221.7 (market cap $78.65B), while Synchrony Financial trades at $72.91 (market cap $23.99B). The key difference: Moderna, Inc. is far larger — about 3.3× Synchrony Financial's market cap, and Synchrony Financial pays a 1.84% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and Synchrony Financial for 29 Days on average.
| MRNA | SYF | |
|---|---|---|
Market Cap | $78.65B | $23.99B |
Volume | 37,373,437 | 3,813,027 |
Sector | Health | Financials |
52-Week High | $203.46 | $88.47 |
52-Week Low | $22.36 | $63.78 |
Typical Hold Time | 59 Days | 29 Days |
Enterprise Value | $74.80B | $24.23B |
Dividend Yield | — | 1.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $214.50, up 9.17% with strong technical momentum. The stock shows bullish moving average signals despite negative profitability metrics, with revenue declining from $18.9B in 2022 to $1.92B in 2025. Recent Nasdaq-100 inclusion creates institutional demand, though Citigroup downgraded to Sell citing valuation concerns after a 500% 2026 rally. The company continues beating EPS expectations despite net losses.
Outlook remains bifurcated between technical strength and fundamental challenges. The cancer vaccine pipeline offers growth potential, but persistent losses and high valuations create headwinds. Near-term momentum may continue from index fund inflows, though profitability concerns warrant caution for long-term investors.
Synchrony Financial (SYF) trades at $72.87, up 1.31% with bullish technical signals despite mixed momentum indicators. The stock shows strong fundamentals with a low P/E of 7.56, robust ROE of 22.23%, and consistent earnings beats. Recent partnerships with OpenAI and Vetspire highlight strategic growth initiatives in AI-driven commerce and veterinary financing.
SYF presents compelling value with attractive valuation metrics and strong profitability, though investors face risks from consumer credit quality and competitive pressures. Analyst consensus targets $87.58 (20% upside) with 61% buy ratings, supporting a positive outlook if the company maintains its earnings trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Synchrony Financial
Synchrony Financial is a premier consumer financial services company and the largest provider of private-label credit cards in the United States. Spun off from GE Capital in 2014, it operates through a unique B2B2C model, embedding its financing products within the ecosystems of major partners like Amazon, Lowe’s, and PayPal. Synchrony leverages deep data analytics and a diverse multi-platform strategy—spanning retail, health, and auto—to drive customer loyalty and provide specialized credit solutions at the point of sale.
Read more on SYF →
